BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial
T Petrella, C Copie-Bergman, J Brière, R Delarue, F Jardin, P Ruminy, C Thieblemont, M Figeac, D Canioni, P Feugier, B Fabiani, K Leroy, M Parrens, M André, C Haioun, G A Salles, P Gaulard, H Tilly, J P Jais, T J Molina, T Petrella, C Copie-Bergman, J Brière, R Delarue, F Jardin, P Ruminy, C Thieblemont, M Figeac, D Canioni, P Feugier, B Fabiani, K Leroy, M Parrens, M André, C Haioun, G A Salles, P Gaulard, H Tilly, J P Jais, T J Molina
Abstract
Background: Our aim was to evaluate whether the cell of origin (COO) as defined by the Hans algorithm and MYC/BCL2 coexpression, which are the two main biological risk factors in elderly patients treated with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisolone (R-CHOP), maintain their prognostic value in a large prospective clinical trial.
Patients and methods: We evaluated 285 paraffin-embedded samples from patients (60-80 years of age) enrolled in the Lymphoma Study Association trial LNH03-6B who were treated with R-CHOP. We correlated the COO defined by the transcriptome according to the Wright algorithm with that defined by the Hans algorithm in a subset of 62 tumors with available frozen tissue samples.
Results: The non-germinal center B-cell-like phenotype according to the Hans algorithm and BCL2 expression (but not MYC and BCL2 coexpression) predicted worse progression-free survival [hazard ratio (HR)=1.78, P = 0.003 and HR = 1.79, P = 0.003, respectively] and overall survival (HR = 1.85, P = 0.005 and HR = 1.67, P = 0.02, respectively) independently of the International Prognostic Index. The correlation between the Hans algorithm and the Wright algorithm was 91%, with an almost perfect concordance according to a kappa test (0.81).
Conclusions: Our results suggest that immunohistochemically defined COO remains a useful tool for predicting prognosis in diffuse large B-cell lymphoma when performed under optimized standardized conditions and that BCL2 expression may help to identify elderly patients at risk for relapse and who could potentially respond to anti-BCL2 targeted agents. In this prospective phase III trial, the coexpression of MYC and BCL2 does not appear to predict worse survival.
Clinical trial number: NCT00144755.
Keywords: BCL2; MYC; cell of origin; diffuse large B-cell lymphoma; immunohistochemistry; prognosis.
© The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Source: PubMed